Literature DB >> 14559922

The fidelity of HPV16 E1/E2-mediated DNA replication.

Ewan R Taylor1, Edward S Dornan, Winifred Boner, Julie A Connolly, Shona McNair, Patricia Kannouche, A R Lehmann, Iain M Morgan.   

Abstract

Human papillomaviruses (HPV) are causative agents in a variety of human diseases; for example over 99% of cervical carcinomas contain HPV DNA sequences. Often in cervical carcinoma the HPV genome is integrated into the host genome resulting in unregulated expression of the viral transforming proteins E6 and E7. Therefore viral integration is a step toward HPV-induced carcinogenesis. Integration of the HPV genome could occur following double-strand DNA breaks that could arise during viral DNA replication. We investigated the fidelity of HPV 16 E1- and E2-mediated DNA replication of non-damaged and UVC-damaged templates in a variety of cell lines with different genetic backgrounds; C33a (derived from an HPV-negative cervical carcinoma), XP30RO (deficient in the by-pass polymerase eta (poleta)), XP30eta (expressing a restored wild-type poleta), XP12RO (nucleotide excision repair defective), and MRC5 (derived from a 14-week-old human fetus). The results demonstrate that the fidelity of E1- and E2-mediated DNA replication is reflective of the genetic background in which the assays are carried out. For example, restoring poleta to the XP30 cell line results in a 3-fold drop in the number of mutants obtained following replication of a UVC-damaged template. A relatively high percentage of the mutant-replicated molecules arise as a result of genetic rearrangement. This is the first time such studies have been carried out with an HPV replication system, and the results are discussed in the context of the HPV life cycle and what is known about HPV genomes in human cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559922     DOI: 10.1074/jbc.M308779200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).

Authors:  Melanie McFarlane; Alasdair I MacDonald; Andrew Stevenson; Sheila V Graham
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

2.  Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus.

Authors:  Tomomi Nakahara; Paul F Lambert
Journal:  Virology       Date:  2007-06-01       Impact factor: 3.616

3.  Werner Helicase Control of Human Papillomavirus 16 E1-E2 DNA Replication Is Regulated by SIRT1 Deacetylation.

Authors:  Dipon Das; Molly L Bristol; Nathan W Smith; Claire D James; Xu Wang; Pietro Pichierri; Iain M Morgan
Journal:  mBio       Date:  2019-03-19       Impact factor: 7.867

Review 4.  Using a Human Papillomavirus Model to Study DNA Replication and Repair of Wild Type and Damaged DNA Templates in Mammalian Cells.

Authors:  Dipon Das; Molly L Bristol; Pietro Pichierri; Iain M Morgan
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

Review 5.  Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence.

Authors:  Katherine M Feeney; Joanna L Parish
Journal:  Proc Biol Sci       Date:  2009-01-20       Impact factor: 5.349

6.  DNA Damage Reduces the Quality, but Not the Quantity of Human Papillomavirus 16 E1 and E2 DNA Replication.

Authors:  Molly L Bristol; Xu Wang; Nathan W Smith; Minkyeong P Son; Michael R Evans; Iain M Morgan
Journal:  Viruses       Date:  2016-06-22       Impact factor: 5.048

7.  Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.

Authors:  Sarah Mole; Arwa Ali A Faizo; Hegel Hernandez-Lopez; Megan Griffiths; Andrew Stevenson; Sally Roberts; Sheila V Graham
Journal:  J Gen Virol       Date:  2020-03-13       Impact factor: 3.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.